Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAIN
NCT02275533Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02275533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275533.